On February 14, 2024 Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, reported that the Company will be attending and presenting at the following upcoming investors conferences (Press release, Kineta, FEB 14, 2024, View Source;utm_medium=rss&utm_campaign=kineta-to-present-at-upcoming-investor-conferences [SID1234640093]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BIO CEO and Investor Conference
Date: Monday, February 26, 2024
Time: 9:45 A.M.- 10:00 A.M. Eastern Time
Format: Presentation and 1:1 meetings
Location: The New York Marriott Marquis, Uris room

10th Annual Immuno-Oncology 360 Conference (IO360)
Date: February 27-29, 2024
Format: 1:1 meetings
Location: New York Marriott at the Brooklyn Bridge

Opal Group Family Office Winter Forum
Date: Monday, March 4, 2024
Time: 12:30 P.M.- 12:50 P.M. Eastern Time
Format: Presentation and 1:1 meetings
Location: etc.venues 360 Madison, New York, NY

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.